about
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.SEOM clinical guidelines in metastatic breast cancer 2015.New target-based agents involve new clinical trial designs.Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.Endocrine therapy of metastatic breast cancer.Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.The dual kinase complex FAK-Src as a promising therapeutic target in cancerPlatinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.Neratinib (HKI-272) in the treatment of breast cancer.Running away from side effects: physical exercise as a complementary intervention for breast cancer patients.Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Review: circulating tumor cells in the practice of breast cancer oncology.Neratinib for the treatment of HER2-positive early stage breast cancer.Endocrine therapy for hormone treatment-naïve advanced breast cancer.Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial.Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.Zooming in on the schedule of bone-modifying drugs.Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer.Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital.Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.S-1 versus taxanes for HER2-negative metastatic breast cancer.Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase geneCirculating tumor cells in metastatic breast cancer: timing of blood extraction for analysisOsteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acidSignificance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal CarcinomaBreast metastases as the first sign of recurrence of a cutaneous melanomaEpididymal metastases as the first sign of a colon cancer recurrenceCuirasse skin metastases secondary to gastric adenocarcinomaInterstitial Pneumonitis and Lung Fibrosis during Adjuvant Treatment of Melanoma with Interferon Alpha according to the Kirkwood ScheduleThe dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm
P50
Q36021424-535AF2EF-409A-47A7-BF7E-58625C7D7E00Q36400360-34B48C5D-4605-4EA3-91E4-A63431CB0360Q36585602-D988C3C8-5649-4288-9B07-D05445DDF606Q37208730-3842E7CD-102A-422E-8FF6-3F4176DC5268Q37230676-F3F517AC-F46A-445B-B133-66E5638B6317Q37364879-8FAF96CA-FC9E-44BA-A433-4D730EAFFE4EQ37771259-A8C790F3-39E6-4EFD-8B14-54F4F8C0F8ADQ37842973-82BF646B-A9E9-4E4A-BEE8-5B97156376ABQ38024121-4AE4C702-7371-4C6E-81A5-F087CC2849A4Q38217448-C614AD29-5334-4DF2-B34F-A3AAEEFB69B0Q38649485-FE4CEDD9-744E-4AEB-8762-FB1FC61322EEQ38662712-C48068A2-69C6-445A-98D8-62DCB8DB3791Q38666768-4934BF06-372F-43E6-9252-617E1AFCC9DBQ38871878-8C65F937-8C10-46DF-A163-112252AF280CQ39683758-52B1FBFC-BCE8-4F60-97C7-814AF54C93A0Q39707035-3A6D9FA5-92CE-40EF-88D4-61134BD9B2EDQ41465790-0897CB46-52CA-4352-9E37-A60A3DF893ACQ42371389-AB4E9775-EED4-47D6-BA24-AE1F5CF5A299Q42486311-0E157722-3D61-42DA-83A1-53B746F67768Q42491917-4DD84F95-45B0-43C9-BEDB-8B7A8ABCE1C4Q43181369-83507A03-C189-43A8-A394-D526001E7575Q45359116-D6A46D58-D4CC-4835-9558-296625E1D2F8Q46496675-D58658F0-3784-4463-8EC4-8A3656A90390Q46796810-AFABD1A3-9410-48F6-832C-2F7CC991F4DDQ47191699-546A79B1-B1F8-4F75-B848-3847B4338395Q47321026-AD371103-4B92-4A5F-A323-3904BBAADAE7Q47629726-E5B76870-FA8E-4B57-8E02-DD3F063359F4Q48104335-46B8856B-AFD3-4D66-BD58-64E11F761A3FQ48148198-00A47ED4-DDA0-4EBE-92E6-C4C3CCC2D0DDQ48571547-6F360D13-AD52-4DA4-BEEE-8ECB73E69E72Q53260862-67503244-646F-48EB-BA69-C35CF6E952C8Q57815793-A8EC3649-0E8B-4410-BDF7-AE3DEBACC758Q58371712-E2D78334-AC0F-4ED8-8DBB-017A2845B435Q61917220-1A32E410-EEA3-4A28-85B9-1821F66F795BQ61917228-CF6FB6DE-BE80-4CB0-898D-E7B418CEFCCEQ61917248-4D0FCADD-A5C9-4BDA-B6E4-0AB938146A3AQ61917251-693E075B-62D0-4E5D-BC48-2822A640378FQ61917253-35B61B3A-97A5-4A6A-A5AC-D7AC2D8A660DQ61917259-C38EC4A1-7242-4174-8628-08CB246BF615Q80139015-9C740FFC-FB31-406E-B8A4-9C7AFD3D7E82
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sara López-Tarruella
@ast
Sara López-Tarruella
@en
Sara López-Tarruella
@es
Sara López-Tarruella
@nl
type
label
Sara López-Tarruella
@ast
Sara López-Tarruella
@en
Sara López-Tarruella
@es
Sara López-Tarruella
@nl
prefLabel
Sara López-Tarruella
@ast
Sara López-Tarruella
@en
Sara López-Tarruella
@es
Sara López-Tarruella
@nl
P106
P21
P31
P496
0000-0002-2606-9538